Market Movers: Ikena Oncology (IKNA) Gains 13.39% to Close at $4.15 June 23

Equities Staff  |

Today, Ikena Oncology Inc (NASDAQ:IKNA) was up $0.49 to end the day Thursday at $4.15.

The company opened at $3.57 and shares fluctuated between $4.15 and $3.37 with 330,477 shares trading hands.

Ikena Oncology is averaging 277,217 shares traded over the last 30 days. They have lost 70.81% YTD.

Ikena Oncology is set to release earnings on 2022-08-11.

For technical charts, analysis, and more on Ikena Oncology visit the company profile.

About Ikena Oncology Inc

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs.

To get more information on Ikena Oncology Inc and to follow the company's latest updates, you can visit the company's profile page here: Ikena Oncology Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content